In short
Clinical trials are investigating ZAMPILIMAB in people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. These studies aim to find a dose that is safe and effective, and to measure changes in lung function. The main target population is adults with IPF.
Key points
- ZAMPILIMAB is being studied in a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). The study is authorised and plans to include 235 participants. Researchers want to find an effective and safe dose and compare results with placebo. The main measurement is change in percent predicted forced vital capacity, or ppFVC, at Week 24. This trial focuses on adults with IPF and looks at whether ZAMPILIMAB can improve lung function.
Trial overview
The available trial data show one authorised study of ZAMPILIMAB in people with idiopathic pulmonary fibrosis, also called IPF. The study title says it is looking for an efficacious and safe dose of CHF10067, which is identified as zampilimab in the source data.
This is an interventional clinical trial, which means researchers give a study treatment and then measure the results. The trial is authorised and plans to enrol 235 participants.
Condition studied and who can join
The trial is for participants with idiopathic pulmonary fibrosis. IPF is a lung disease that causes scarring and can reduce breathing ability; the trial data do not provide more detail about symptoms or disease stage.
The source data do not list full entry rules such as age limits, test results, or previous treatments. Based on the available information, the target population is people living with IPF.
Treatment and comparison
The study intervention includes ZAMPILIMAB given by intravenous infusion, which means it is delivered into a vein. The trial data also mention 0.9% sodium chloride aqueous solution for IV infusion as the comparison treatment.
The brief summary says the study is evaluating two dose strengths of CHF10067 and comparing them with placebo in the entire study population. In simple words, the trial is checking whether different doses work better than a non-active comparison treatment.
Study phase and design
This is a Phase 2 study. Phase 2 trials usually focus on whether a treatment may help and continue to watch safety in a larger group than early studies, but the source data only confirm the phase and do not add more design details.
The study is listed as interventional and authorised, with an expected enrolment of 235 participants. The available data do not describe randomisation, masking, or how many study groups there are.
What the trial measures
The primary outcome is measured at Week 24. The main endpoint is the change from baseline in percent predicted forced vital capacity, or ppFVC, compared with placebo in the whole study population.
Forced vital capacity is a lung function test that shows how much air a person can breathe out after taking a deep breath. 'Percent predicted' means the result is compared with what would be expected for someone of similar age, sex, height, and background.
Why this trial matters for patients
For people with IPF, lung function can slowly get worse over time, so studies that measure breathing tests are important. This trial is designed to see whether ZAMPILIMAB can improve or preserve lung function better than placebo over 24 weeks.
Because only one trial is provided in the source data, the current picture is limited to this Phase 2 study in IPF. The most important facts from the available record are the condition studied, the authorised status, the planned enrolment of 235 participants, and the focus on ppFVC at Week 24.